A management system for elderly patients with moderate to severe aortic stenosis

Study on the management system of elderly patients with aortic valve stenosis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400088895

Enrollment

Unknown

Registered

2024-08-28

Start date

2024-09-01

Completion date

Unknown

Last updated

2024-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aortic valve stenosis in the elderly

Interventions

SnNON:Standard management The standard management team would be asked to visit the hospital at a set time: every six months for the non-surgical group

The examination contents include: electrocardiogram, blood routine, liver and kidney function, electrolyte, BNP, heart color ultrasound, etc. In addition, we will conduct a telephone follow-up to the

SNOO:Standard management The standard management team would be asked to visit the hospital at a set time: The surgical group was examined every 1, 3, 6, and 12 months after surgery and every year the

CnNON:Non-standard management group: Patients in this group did not set follow-up management plan according to this study, and followed up on their own.

CNOO:Non-standard management group: Patients in this group did not set follow-up management plan according to this study, and followed up on their own.

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: a. Patients that older than 65 years; b. Clear diagnosis of moderate and severe aortic stenosis.

Exclusion criteria

Exclusion criteria: a) Have implanted artificial heart valve, artificial ring, and severe mitral calcification; b) Acute coronary event occurred within 1 month, requiring revascularization but left untreated; c) Hemodynamic instability, requiring cardiotonic drug support or mechanical cardiac assistance; d) With infective endocarditis or other active infection; e) Hypertrophic cardiomyopathy, with or without obstruction; f) Echocardiography showed intracardiac thrombus or neoplasm; g) Had any therapeutic or traumatic heart surgery within 30 days; h) Active peptic ulceration or upper gastrointestinal bleeding within 3 months; i) Cerebrovascular events within 6 months; j) With an estimated life span of <12 months.

Design outcomes

Primary

Measure	Time frame
Maximum pressure difference;Average pressure difference;Maximum velocity value at the stenosis;Aortic valve opening area;The inner diameter of the valve ring;left ventricular ejection fraction;interventricular septal thickness;Left ventricular ejection fraction, LVEF;Left artriumdiameter, LAD;Left ventricular end diastolic diameter, LVEDD;Right artriumdiameter, RAD;Right ventricular end diastolic diameter, RVEDD;	—

Measure

Time frame

Maximum pressure difference;Average pressure difference;Maximum velocity value at the stenosis;Aortic valve opening area;The inner diameter of the valve ring;left ventricular ejection fraction;interventricular septal thickness;Left ventricular ejection fraction, LVEF;Left artriumdiameter, LAD;Left ventricular end diastolic diameter, LVEDD;Right artriumdiameter, RAD;Right ventricular end diastolic diameter, RVEDD;

—

Secondary

Measure	Time frame
The number of lobes;Classification of calcification degree;Valve thickness;Electrocardiogram data;Serological indicators;	—

Countries

China

Contacts

Public ContactYong Peng

The West China Hospital of Sichuan University

pengyongcd@126.com+86 189 8060 6696

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026